{"entity":{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","aka":[],"tldr":"Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG.","summary":"Stephen Boorjian chairs the department of urology at Mayo Clinic in Rochester. He was first author of the 2021 Lancet Oncology report of the phase 3 trial of intravesical nadofaragene firadenovec, an adenoviral vector delivering the interferon alfa-2b gene, in BCG-unresponsive non-muscle-invasive bladder cancer; about half of patients with carcinoma in situ had a complete response, the basis of the first gene therapy approval in bladder cancer. He also publishes on outcomes after cystectomy and nephrectomy.","asOf":"2026-09-18","links":[],"tags":["urothelial","gene-therapy","surgery","trialist"],"related":[],"cancers":["non-muscle-invasive-bladder-cancer","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nadofaragene-firadenovec-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Urology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Bladder cancer","Intravesical therapy","Urological surgery outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boorjian%5BAuthor%5D"}],"papers":[]},"route":"/people/stephen-boorjian/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"}],"paper":[{"id":"paper-nadofaragene-firadenovec-lancet-oncol-2021","kind":"paper","name":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/"}]}}